Intraoperative imaging technology cuts need for repetitive lumpectomy

Lightpoint Medical, developers of medical imaging technologies, has announced results for its clinical trial in regards to intraoperative imaging technology for breast cancer surgery.

"These pilot clinical trial results are an important step in Lightpoint Medical's mission to provide clinicians with more accurate tools to guide cancer surgery,” said David Tuch, MD, CEO of Lightpoint Medical. “We look forward to undertaking further clinical trials to validate these results in larger patient populations."

As the primary treatment for early-stage breast cancer, lumpectomies are often performed more than once on patients due to the lack of precision in detecting cancer. For the 25 percent of patients needing a second breast-conserving surgery, intraoperative molecule imaging could be able to assess the extent of cancer on the first try and avoid repeat operations.

In the first human clinical trial, intraoperative molecular imaging was found to be a low cost, effective and feasible procedure for assessing tumor margin intraoperatively.

"We're delighted to present these exciting first-in-human results on the use of intraoperative molecular imaging in breast-conserving surgery,” said Arnie Purushotham, with King's College and Guy's Hospital in London. “This clinical trial showed that molecular imaging agreed strongly with gold standard pathology and was straight-forward to interpret. Although the technology is still in its early days, we believe intraoperative molecular imaging holds considerable promise for improving clinical outcomes in breast cancer patients."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.